Form 4: TELA Bio Director Receives Equity Compensation
Statement of Changes in Beneficial Ownership
Director Betty Jo Rocchio acquired 11,675 restricted stock units and 17,335 stock options as part of annual equity compensation.
Summary
- Director Betty Jo Rocchio was granted 11,675 restricted stock units (RSUs) on June 9, 2026.
- The director also received a stock option grant for 17,335 shares with an exercise price of $0.935 per share.
- Both the RSUs and the stock options are scheduled to vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a change in control.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.
Positives
- Equity grants align the interests of the director with those of the shareholders.
- The grants are subject to continued service, incentivizing long-term retention.
Negatives
- The issuance of new equity results in minor dilution to existing shareholders.
Risks
- Vesting is contingent upon continued service, which could be impacted by unforeseen departures.
- The value of the equity is subject to market volatility in TELA Bio's share price.
Future Outlook
The equity awards are subject to standard vesting conditions tied to service and time, with a long-term expiration date of June 2036 for the options.
Industry Context
StockSavvy.ai notes that standard equity compensation for board members is a routine corporate governance practice intended to ensure alignment between leadership and shareholder interests in the medical technology sector.
Comparison to Industry Standards
- The grant structure follows standard industry practices for non-employee director compensation.
- Vesting schedules tied to annual meetings are common among small-cap biotech and medical device companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Issuance of RSUs and options to a director under the 2019 Equity Incentive Plan. | 06/09/2026 | Standard alignment of director interests with shareholders. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on June 9, 2027, or the next annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of transaction and grant of equity awards. |
| 06/11/2026 | Date of filing. |
| 06/09/2027 | Scheduled vesting date for RSUs and options. |
| 06/09/2036 | Expiration date for stock options. |
Keywords
TELA Bio, TELA, Director Compensation, Insider Trading, Equity Incentive Plan, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.